Effective chemotherapy of heterogeneous and drug-resistant early colon cancers by intermittent dose schedules: a computer simulation study
- 207 Downloads
The effectiveness of cancer chemotherapy is limited by intra-tumor heterogeneity, the emergence of spontaneous and induced drug-resistant mutant subclones, and the maximum dose to which normal tissues can be exposed without adverse side effects. The goal of this project was to determine if intermittent schedules of the maximum dose that allows colon crypt maintenance could overcome these limitations, specifically by eliminating mixtures of drug-resistant mutants from heterogeneous early colon adenomas while maintaining colon crypt function.
A computer model of cell dynamics in human colon crypts was calibrated with measurements of human biopsy specimens. The model allowed simulation of continuous and intermittent dose schedules of a cytotoxic chemotherapeutic drug, as well as the drug’s effect on the elimination of mutant cells and the maintenance of crypt function.
Colon crypts can tolerate a tenfold greater intermittent dose than constant dose. This allows elimination of a mixture of relatively drug-sensitive and drug-resistant mutant subclones from heterogeneous colon crypts. Mutants can be eliminated whether they arise spontaneously or are induced by the cytotoxic drug.
An intermittent dose, at the maximum that allows colon crypt maintenance, can be effective in eliminating a heterogeneous mixture of mutant subclones before they fill the crypt and form an adenoma.
KeywordsDrug resistance Heterogeneity Dose schedules Intermittent Colon cancer Adenoma Crypt
We thank Rafael Bravo for writing the code for the original colon crypt model, Dr. Steven Schiff for providing human biopsy specimens, members of the Division of Life Sciences IT Support Group for computer services, RUCore staff for file archive services, and Uri Wilensky for making available the NetLogo open-source application.
DEA. conceived the project, analyzed and interpreted the simulation results, and wrote the manuscript. SV and DEA. carried out the simulations. JO and DEA wrote the revised the code. All authors approved the manuscript.
Compliance with ethical standards
The Human Genetics Institute of New Jersey, the New Jersey Breast Cancer Research Fund, and the Rutgers Cancer Institute of New Jersey (PA30CA072720).
Conflict of interest
The authors declare that they have no conflict of interest.
D.E.A. obtained coded de-identified slides containing sections from biopsies of the sigmoid colon of normal patients enrolled in a clinical research study of Dr. Steven Shiff, Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey. Individualized information about the identity of the subjects and specific clinical information were not made available to D.E.A. Dr. Shiff received approval Reference Number 4611 from the Institutional Review Board for Research Study Involving Human Subjects. The approved protocol included informed consent of participants.
- 8.Enriquez-Navas PM, Kam Y, Das T, Hassen S, Silva A, Foroutan P, Rulz E, Martinez G, Minton S, Gilles RJ, Gatenby RA (2016) Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer. Sci Trans Med 8:325ra24. doi: 10.1126/scitranslmed.aad7842
- 12.Venkatakrishnan K, Friberg LE, Ouellet D, Mettetal JT, Stein A, Trocóniz IF, Bruno R, Mehrotra N, Gobburu J, Mould DR (2015) Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities. Clin Pharmacol Ther 97:37–54. doi: 10.1002/cpt.7 CrossRefPubMedGoogle Scholar
- 18.Borras E, San Lucas FA, Chang K, Zhou R, Masand G, Fowler J, Mor ME, You YN, Taggart MW, McAllister F, Jones DA, Davies GE, Edelmann EA, Ehli EA, Lynch PM, Hwak ET, Capella G, Scheet PI, Vlar E (2016) Genomic landscape of colorectal mucosa and adenomas. Cancer Prev Res 9:417–427CrossRefGoogle Scholar
- 27.Cox JD (1988) Time, dose, and fractionation in radiation therapy: An historical perspective. In: Vaeth JM, Meyer J (eds) Time, dose and fractionation in the radiation therapy of cancer: a frontier revisited. Karger, Basel, pp 14–18Google Scholar
- 30.Beex L, Rose C, Mouridsen H, Jassem J, Nooij M, Estape J, Paridaens R, Piccart M, Gorlia T, Lardenoije S, Baila L (2006) Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: an EORTC phase III study (10863). Eur J Cancer 42:3178–3185CrossRefPubMedGoogle Scholar
- 33.Maughan TS, James RD, Kerr DJ, Ledermann JA, Seymour MT, Topham C, McArdle C, Cain D, Stephens RJ, Medical Research Council Colorectal Cancer Group (2003) Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet 361:457–464CrossRefPubMedGoogle Scholar
- 34.Van Cutsem E, Findlay M, Osterwalder B, Kocha W, Dalley D, Pazdur R, Cassidy J, Dirix L, Twelves C, Allman D, Seitz JF, Schölmerich J, Burger HU, Verweij J (2000) Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol 18:1337–1345CrossRefPubMedGoogle Scholar
- 35.Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Etienne P, Rivera F, Chirivella I, Perez-Staub N, Louvet C, André T, Tabah-Fisch I, de Gramont A (2006) OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer—a GERCOR study. J Clin Oncol 24:294–440CrossRefGoogle Scholar
- 36.Adams RA, Meade AM, Seymour MT, Wilson RH, Madi A, Fisher D, Kenny SL, Kay E, Hodgkinson E, Pope M, Rogers P, Wasan H, Falk S, Gollins S, Hickish T, Bessell EM, Propper D, Kennedy MJ, Kaplan R, Maughan TS, MRC COIN Trial Investigators (2011) Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol 12:642–653. doi: 10.1016/S1470-2045(11)70102-4 CrossRefPubMedPubMedCentralGoogle Scholar
- 43.Krishn SR, Kaur S, Smith LM, Johansson SL, Jain M, Patel A, Gautam SK, Hollingsworth MA, Mandel U, Clausen H, Lo WC, Fan WT, Manne U, Batra SK (2016) Mucins and associated glycan signatures in colon adenoma-carcinoma sequence: prospective pathological implications(s) for early diagnosis of colon cancer. Cancer Lett 374:304–341. doi: 10.1016/j.canlet.2016.02.016 CrossRefPubMedGoogle Scholar
- 44.Rossez Y, Burtea C, Laurent S, Gossset P, Léonard R, Gonzalez W, Ballet S, Raynal I, Rousseaux O, Dugué T, vander Elst L, Jichalski J-C, Muller RN Robbe-Masselot C (2016) Early detection of colonic dysplasia by magnetic resonance molecular imaging with a contrast agent raised against colon cancer marker MUC5AC. Contrast Media Mol Imaging 11:211–221. doi: 10.1002/cmmi.1682 CrossRefPubMedGoogle Scholar